These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35577139)

  • 1. A systematic study on phenotypical characteristics of invasive breast carcinoma and surrounding ductal carcinoma in situ in multifocal breast cancers.
    Jeon T; Kim H; Kim A; Kim C
    Hum Pathol; 2022 Sep; 127():12-20. PubMed ID: 35577139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of B-cell lymphoma 2 immunoexpression in invasive carcinoma of breast, no special type with hormone receptor status, proliferation index, and molecular subtypes.
    Azmat H; Faridi J; Habib HM; Bugti UJ; Sheikh AK; Riaz SK
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S313-S319. PubMed ID: 36510982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
    Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
    Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer.
    Kurbel S
    Tumour Biol; 2013 Feb; 34(1):1-7. PubMed ID: 23208673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model of immunohistochemical differences between invasive breast cancers and DCIS lesions tested on a consecutive case series of 1248 patients.
    Kurbel S; Marjanović K; Dmitrović B
    Theor Biol Med Model; 2014 Jun; 11():29. PubMed ID: 24917206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast.
    Perez AA; Rocha RM; Balabram D; Souza Áda S; Gobbi H
    Clinics (Sao Paulo); 2013 May; 68(5):674-8. PubMed ID: 23778408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion.
    Wan ZB; Gao HY; Wei L; Zhang AQ; Zhang JY; Wang Y; Wang DD; Zhang Y
    Medicine (Baltimore); 2018 Nov; 97(44):e13055. PubMed ID: 30383678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical profile and clinical-pathological variables in breast cancer.
    Cintra JR; Teixeira MT; Diniz RW; Gonçalves Junior H; Florentino TM; Freitas GF; Oliveira LR; Neves MT; Pereira T; Guerra MR
    Rev Assoc Med Bras (1992); 2012; 58(2):178-87. PubMed ID: 22569612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.
    Ono M; Tsuda H; Yunokawa M; Yonemori K; Shimizu C; Tamura K; Kinoshita T; Fujiwara Y
    Breast Cancer; 2015 Mar; 22(2):141-52. PubMed ID: 23584595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.
    Kakudji BK; Mwila PK; Burger JR; du Plessis JM; Naidu K
    Pan Afr Med J; 2021; 38():85. PubMed ID: 33889251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.
    Tamimi RM; Baer HJ; Marotti J; Galan M; Galaburda L; Fu Y; Deitz AC; Connolly JL; Schnitt SJ; Colditz GA; Collins LC
    Breast Cancer Res; 2008; 10(4):R67. PubMed ID: 18681955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.
    Aleskandarany MA; Green AR; Benhasouna AA; Barros FF; Neal K; Reis-Filho JS; Ellis IO; Rakha EA
    Breast Cancer Res; 2012 Jan; 14(1):R3. PubMed ID: 22225836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.